Supernus Pharmaceuticals annual cash and equivalents
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Supernus Pharmaceuticals Cash & Equivalents Growth & History (SUPN)
Supernus Pharmaceuticals's cash and equivalents was $128.4M for fiscal 2025.
View full Supernus Pharmaceuticals company overviewSupernus Pharmaceuticals annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $128.4M | $59.1M | +85.27% |
| 2024 | 2024-12-31 | $69.3M | −$5.7M | −7.63% |
| 2023 | 2023-12-31 | $75.1M | −$18.1M | −19.40% |
| 2022 | 2022-12-31 | $93.1M | −$110.3M | −54.23% |
| 2021 | 2021-12-31 | $203.4M | −$85.2M | −29.52% |
| 2020 | 2020-12-31 | $288.6M | $107.3M | +59.13% |
| 2019 | 2019-12-31 | $181.4M | −$10.9M | −5.65% |
| 2018 | 2018-12-31 | $192.2M | $91.9M | +91.67% |
| 2017 | 2017-12-31 | $100.3M | $33.9M | +51.06% |
| 2016 | 2016-12-31 | $66.4M | $32.9M | +98.21% |
| 2015 | 2015-12-31 | $33.5M | −$2.9M | −7.96% |
| 2014 | 2014-12-31 | $36.4M | $3.4M | +10.36% |
| 2013 | 2013-12-31 | $33.0M | −$7.3M | −18.17% |
| 2012 | 2012-12-31 | $40.3M | −$8.2M | −16.98% |
| 2011 | 2011-12-31 | $48.5M | $24.8M | +104.48% |
| 2010 | 2010-12-31 | $23.7M | — | — |
Supernus Pharmaceuticals quarterly cash and equivalents
Q4.10
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $180.0M | $35.2M | +24.35% |
| Q1 2026 | 2026-03-31 | $184.9M | $69.0M | +59.58% |
| Q4 2025 | 2025-12-31 | $128.4M | $59.1M | +85.27% |
| Q3 2025 | 2025-09-30 | $151.4M | $119.7M | +377.92% |
| Q2 2025 | 2025-06-30 | $144.7M | $92.6M | +177.81% |
| Q1 2025 | 2025-03-31 | $115.8M | $52.4M | +82.72% |
| Q4 2024 | 2024-12-31 | $69.3M | −$5.7M | −7.63% |
| Q3 2024 | 2024-09-30 | $31.7M | −$63.3M | −66.65% |
| Q2 2024 | 2024-06-30 | $52.1M | $27.4M | +110.84% |
| Q1 2024 | 2024-03-31 | $63.4M | $5.0M | +8.49% |
| Q4 2023 | 2023-12-31 | $75.1M | −$18.1M | −19.40% |
| Q3 2023 | 2023-09-30 | $95.0M | −$16.5M | −14.81% |
| Q2 2023 | 2023-06-30 | $24.7M | −$148.7M | −85.75% |
| Q1 2023 | 2023-03-31 | $58.4M | −$57.3M | −49.49% |
| Q4 2022 | 2022-12-31 | $93.1M | −$110.3M | −54.23% |
| Q3 2022 | 2022-09-30 | $111.5M | −$103.8M | −48.21% |
| Q2 2022 | 2022-06-30 | $173.4M | −$50.3M | −22.50% |
| Q1 2022 | 2022-03-31 | $115.7M | −$139.9M | −54.74% |
| Q4 2021 | 2021-12-31 | $203.4M | −$85.2M | −29.52% |
| Q3 2021 | 2021-09-30 | $215.3M | $11.0M | +5.38% |
| Q2 2021 | 2021-06-30 | $223.8M | $12.8M | +6.07% |
| Q1 2021 | 2021-03-31 | $255.6M | $29.9M | +13.23% |
| Q4 2020 | 2020-12-31 | $288.6M | $107.3M | +59.13% |
| Q3 2020 | 2020-09-30 | $204.3M | $87.4M | +74.78% |
| Q2 2020 | 2020-06-30 | $211.0M | $123.6M | +141.54% |
| Q1 2020 | 2020-03-31 | $225.8M | $103.0M | +83.88% |
| Q4 2019 | 2019-12-31 | $181.4M | −$10.9M | −5.65% |
| Q3 2019 | 2019-09-30 | $116.9M | −$6.9M | −5.60% |
| Q2 2019 | 2019-06-30 | $87.3M | $52.1M | +148.10% |
| Q1 2019 | 2019-03-31 | $122.8M | −$321.4M | −72.36% |
| Q4 2018 | 2018-12-31 | $192.2M | $91.9M | +91.67% |
| Q3 2018 | 2018-09-30 | $123.8M | $41.9M | +51.14% |
| Q2 2018 | 2018-06-30 | $35.2M | −$26.5M | −42.98% |
| Q1 2018 | 2018-03-31 | $444.1M | $384.5M | +645.21% |
| Q4 2017 | 2017-12-31 | $100.3M | $33.9M | +51.06% |
| Q3 2017 | 2017-09-30 | $81.9M | $27.6M | +50.86% |
| Q2 2017 | 2017-06-30 | $61.7M | $25.6M | +70.75% |
| Q1 2017 | 2017-03-31 | $59.6M | $39.8M | +200.55% |
| Q4 2016 | 2016-12-31 | $66.4M | $32.9M | +98.21% |
| Q3 2016 | 2016-09-30 | $54.3M | $28.7M | +111.79% |
| Q2 2016 | 2016-06-30 | $36.2M | $3.0M | +9.20% |
| Q1 2016 | 2016-03-31 | $19.8M | −$6.0M | −23.17% |
| Q4 2015 | 2015-12-31 | $33.5M | −$2.9M | −7.96% |
| Q3 2015 | 2015-09-30 | $25.6M | −$12.1M | −32.13% |
| Q2 2015 | 2015-06-30 | $33.1M | $21.2M | +176.93% |
| Q1 2015 | 2015-03-31 | $25.8M | $13.6M | +110.66% |
| Q4 2014 | 2014-12-31 | $36.4M | $3.4M | +10.36% |
| Q3 2014 | 2014-09-30 | $37.8M | — | — |
| Q2 2014 | 2014-06-30 | $12.0M | −$22.0M | −64.74% |
| Q1 2014 | 2014-03-31 | $12.3M | −$6.7M | −35.21% |
| Q4 2013 | 2013-12-31 | $33.0M | −$7.3M | −18.17% |
| Q2 2013 | 2013-06-30 | $33.9M | −$13.3M | −28.23% |
| Q1 2013 | 2013-03-31 | $18.9M | $3.0M | +19.18% |
| Q4 2012 | 2012-12-31 | $40.3M | −$8.2M | −16.98% |
| Q3 2012 | 2012-09-30 | $23.4M | — | — |
| Q2 2012 | 2012-06-30 | $47.2M | — | — |
| Q1 2012 | 2012-03-31 | $15.9M | — | — |
| Q4 2011 | 2011-12-31 | $48.5M | $24.8M | +104.47% |
| Q4 2010 | 2010-12-31 | $23.7M | — | — |
Supernus Pharmaceuticals cash and equivalents trends
Over the last five fiscal years, Supernus Pharmaceuticals's cash and equivalents decreased from $288.6M to $128.4M, a change of −$160.2M. The latest reported quarter, Q2 2026, shows $180.0M.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Supernus Pharmaceuticals source filings ↗Community posts
Supernus and Indivior report sales growth ahead of their expected merger closing
Supernus ($SUPN) reported third-quarter 2026 revenue of $226.8 million, up 18%, with Qelbree sales increasing 12% to $90.8 million and Onapgo contributing $17.1 million. Separately, merger partner Indivior ($INDV) posted revenue of $356 mil ...
Supernus confirms ONAPGO exclusivity and seeks a second supplier
Supernus ($SUPN) said the FDA has recognized orphan-drug exclusivity for ONAPGO, its apomorphine infusion treatment for motor fluctuations in adults with advanced Parkinson's disease. The seven-year protection period runs from the medicine' ...
